- Trials with a EudraCT protocol (54)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
54 result(s) found for: Specific appetite.
Displaying page 1 of 3.
EudraCT Number: 2018-004829-82 | Sponsor Protocol Number: GHREDECIDE | Start Date*: 2019-04-16 |
Sponsor Name:Linköping University | ||
Full Title: Effects of the appetite-inducing hormone ghrelin on decision making in healthy volunteers | ||
Medical condition: NA, healthy volunteers | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004831-35 | Sponsor Protocol Number: TACT | Start Date*: 2018-04-09 |
Sponsor Name:Dept of Psychiatry, Umeå University Hospital | ||
Full Title: TACT –Thiamine in Anorexia Clinical Trial | ||
Medical condition: Patients with Anorexia Nervosa and Healthy Controls | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-004180-13 | Sponsor Protocol Number: OCARINA | Start Date*: 2021-10-18 | ||||||||||||||||
Sponsor Name:KU Leuven | ||||||||||||||||||
Full Title: The effect of obeticholic acid on gut microbiota, gastric motility, accommodation, gastrointestinal peptide in healthy volunteers | ||||||||||||||||||
Medical condition: The study will focus on the underlying mechanisms of gastrointestinal motility and gut microbiota in healthy subjects. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2024-000001-33 | Sponsor Protocol Number: C4591048 | Start Date*: 2024-02-07 | |||||||||||||||||||||
Sponsor Name:BioNTech SE | |||||||||||||||||||||||
Full Title: A Master Phase 1/2/3 Protocol to Investigate the Safety, Tolerability, and Immunogenicity of Variant-Adapted BNT162b2 RNA-Based Vaccine Candidate(s) in Healthy Children | |||||||||||||||||||||||
Medical condition: Protection against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-000550-12 | Sponsor Protocol Number: 2014-PT026 | Start Date*: 2014-07-23 | |||||||||||
Sponsor Name:XBiotech Germany GmbH | |||||||||||||
Full Title: A Double Blind, Placebo Controlled, Pivotal Phase III Study Evaluating Xilonix™ in Symptomatic Colorectal Cancer Patients Refractory To Standard Therapy | |||||||||||||
Medical condition: Symptomatic Colorectal Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) GB (Completed) PL (Completed) DE (Prematurely Ended) CZ (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004289-20 | Sponsor Protocol Number: MK-7902-017 | Start Date*: 2021-04-14 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase 3 Randomized Study of Lenvatinib in Combination with Pembrolizumab Versus Standard of Care in Participants with Metastatic Colorectal Cancer Who Have Received and Progressed On or After or ... | |||||||||||||
Medical condition: Colorectal Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001309-60 | Sponsor Protocol Number: MK4280A-007 | Start Date*: 2021-10-08 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase 3 study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PD-L1 positive Colorectal Cancer | |||||||||||||
Medical condition: Metastatic Colorectal Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Temporarily Halted) DE (Completed) CZ (Completed) NO (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003019-24 | Sponsor Protocol Number: 80-87200-98-1017 | Start Date*: 2021-08-18 |
Sponsor Name:University Medical Center Utrecht | ||
Full Title: Effectiveness of analgesic ear drops as add-on treatment to oral analgesics in children with acute otitis media: a pragmatic randomised controlled trial | ||
Medical condition: Acute otitis media | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2014-002386-30 | Sponsor Protocol Number: 33-04 | Start Date*: 2015-02-20 | |||||||||||
Sponsor Name:Verein für Krebsforschung | |||||||||||||
Full Title: Efficacy and Safety of Mistletoe Extract in the Palliative Therapy of Patients Suffering from Pancreatic Cancer (PALM-Pan) | |||||||||||||
Medical condition: Locally advanced or metastatic adenocarcinoma of the pancreas (UICC stadium III or IV) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-009366-13 | Sponsor Protocol Number: TDE-PH-308 | Start Date*: 2009-09-02 | |||||||||||
Sponsor Name:United Therapeutics Corporation | |||||||||||||
Full Title: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arterial Hyp... | |||||||||||||
Medical condition: Pulmonary Arterial Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) NL (Completed) BE (Completed) AT (Completed) DE (Completed) ES (Completed) SE (Completed) PT (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000801-50 | Sponsor Protocol Number: TDE-PH-302 | Start Date*: 2007-02-19 | |||||||||||
Sponsor Name:United Therapeutics Corporation | |||||||||||||
Full Title: A 12-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects with Pulmonary Arteria... | |||||||||||||
Medical condition: Idiopathic or Familial pulmonary arterial hypertension (PAH), including PAH associated with: 1) Appetite suppressant/toxin use, or 2) Repaired congenital systemic-to-pulmonary shunts (repaired ≥... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) FR (Completed) BE (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013885-14 | Sponsor Protocol Number: P06-10/BF2.649 | Start Date*: 2009-11-12 | ||||||||||||||||
Sponsor Name:BIOPROJET | ||||||||||||||||||
Full Title: A randomized, multicenter 12-Week double-blind placebo-controlled study to assess the efficacy and safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson?s disease followed by a 38-Week ope... | ||||||||||||||||||
Medical condition: Excessive daytime sleepiness in Parkinson?s Disease Somnolencia diurna excesiva en la enfermedad de Parkinson. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-013886-24 | Sponsor Protocol Number: P06-11 / BF2.649 | Start Date*: 2010-03-03 | ||||||||||||||||
Sponsor Name:BIOPROJET | ||||||||||||||||||
Full Title: A randomized, multicenter 12-Week double-blind placebo-controlled study to assess the efficacy and safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson’s disease | ||||||||||||||||||
Medical condition: Excessive daytime sleepiness in Parkinson’s Disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) CZ (Completed) SE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-005442-42 | Sponsor Protocol Number: C4591007 | Start Date*: 2021-04-28 | |||||||||||
Sponsor Name:BioNTech SE | |||||||||||||
Full Title: A PHASE 1, OPEN-LABEL DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY, AND IMMUNOGENICITY AND PHASE 2/3 PLACEBOCONTROLLED, OBSERVER-BLINDED SAFETY, TOLERABILITY, AND IMMUNOGENICITY STUDY OF A S... | |||||||||||||
Medical condition: Protection against COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001151-12 | Sponsor Protocol Number: V114-027 | Start Date*: 2018-11-07 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13™ with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants (PNEU-D... | |||||||||||||
Medical condition: prevention of pneumococcal disease | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006621-22 | Sponsor Protocol Number: COVIC-19-G | Start Date*: 2022-02-14 | |||||||||||
Sponsor Name:DRK-Blutspendedienst Baden-Württemberg - Hessen gGmbH | |||||||||||||
Full Title: A Randomised Open-Label Trial of Early, Very High-Titre Convalescent Plasma Therapy in Clinically Vulnerable Individuals with Mild COVID-19 as model of early treatment in a pandemia with a new path... | |||||||||||||
Medical condition: Clinically Vulnerable Individuals with Mild COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022757-42 | Sponsor Protocol Number: IMM-101-002 | Start Date*: 2011-05-17 | |||||||||||
Sponsor Name:Immodulon Therapeutics Limited | |||||||||||||
Full Title: A Randomised, Open-Label, Proof-of-Concept, Phase II Trial Comparing Gemcitabine with and without IMM-101 in Advanced Pancreatic Cancer | |||||||||||||
Medical condition: Advanced pancreatic cancer The overall objective of this clinical study is to evaluate a potential synergy between gemcitabine and IMM-101 and any beneficial effect this may have on safety and to... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) IT (Completed) IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000800-17 | Sponsor Protocol Number: TDE-PH-301 | Start Date*: 2007-02-15 | |||||||||||
Sponsor Name:United Therapeutics Corporation | |||||||||||||
Full Title: A 16-Week International, Multicenter, Double-Blind, Randomized, Placebo Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Combination with an Endothelin... | |||||||||||||
Medical condition: Idiopathic or Familial pulmonary arterial hypertension (PAH), including PAH associated with: 1) Appetite suppressant use, or 2) Repaired congenital systemic-to-pulmonary shunts (repaired ≥ 5 yea... | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) GB (Completed) NL (Completed) AT (Completed) FR (Completed) BE (Completed) IT (Completed) DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003306-27 | Sponsor Protocol Number: B7471012 | Start Date*: 2020-12-03 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE GIVEN AS A SERIES OF 2 INFANT DOSES AND 1 TODDLER DOSE IN HEALTHY I... | |||||||||||||
Medical condition: Pneumococcal Infections | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) CZ (Completed) EE (Completed) FI (Completed) PL (Completed) SK (Completed) DK (Completed) BE (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-006276-11 | Sponsor Protocol Number: VR496/005 | Start Date*: 2008-09-01 | |||||||||||
Sponsor Name:Vectura Limited | |||||||||||||
Full Title: A Phase I/II randomised, placebo-controlled, double blind trial to assess the safety, tolerability, pharmacodynamics and exploratory efficacy of heparin 25 mg inhalation powder in patients with Cys... | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IE (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
